



CERTIFICATE



This is to certify that the company

botiss biomaterials GmbH

Hauptstraße 28 15806 Zossen Germany

with the organizational units/sites as listed in the annex

has implemented and maintains a Quality Management System.

Scope of certification:

Design and development, production and distribution of products for bone and tissue regeneration.

-AUS (a), BRA, CND, JPN, USA (a,b,c,d)

Through an audit, documented in a report, performed by DQS Medizinprodukte GmbH, it was verified that the management system fulfills the requirements of the following standard:

ISO 13485: 2016

including applicable country-specific regulatory requirements, as indicated below the scope (full references of abbreviations are listed in the annex)

Certificate registration no. 525421 MDSAP16

Certificate unique ID 170776680

Effective date 2021-10-04

Expiry date 2024-10-03

Frankfurt am Main 2021-10-04



DQS Medizinprodukte GmbH

1. Mb leuc

Sigrid Uhlemann Managing Director Szymon Kurdyn Product Manager

finon Clerchyn







Annex to certificate

Certificate registration No.: 525421 MDSAP16

Certificate unique ID: 170776680

Effective date: 2021-10-04

botiss biomaterials GmbH

Hauptstraße 28 15806 Zossen Germany

Audited site

REPs FEI No.: site scope and country-specific requirements

529022 botiss biomaterials GmbHUllsteinstraße 108, Aufgang D
12109 Berlin
Germany

Design and development, production, storage, shipment and distribution of products for bone and tissue regeneration.

-AUS (a), BRA, CND, JPN, USA (a,b,c,d)

REPs FEI No.: F002292

525422 botiss biomaterials GmbHHauptstraße 28
15806 Zossen
Germany

Design and development, production, storage, shipment and distribution of products for bone and tissue regeneration.

-AUS (a), BRA, CND, JPN, USA (a,b,c,d)

REPs FEI No.: F001495







Annex to certificate

Certificate registration No.: 525421 MDSAP16

Certificate unique ID: 170776680

Effective date: 2021-10-04

botiss biomaterials GmbH

Hauptstraße 28 15806 Zossen Germany

Full references of country-specific requirements of MDSAP participating Regulatory Authorities

Abbreviation	Jurisdiction	Reference
AUS	Australia	 (a) Therapeutic Goods (Medical Devices) Regulations 2002, Schedule 3, Part 1 – Full Quality Assurance Procedure (b) Therapeutic Goods (Medical Devices) Regulations 2002, Schedule 3, Part 4 – Production Quality Assurance Procedure
BRA	Brazil	RDC ANVISA n. 16/2013 RDC ANVISA n. 23/2012 RDC ANVISA n. 67/2009
CND	Canada	Medical Device Regulations SOR/98-282, Part 1
JPN	Japan	MHLW Ministerial Ordinance No. 169 (2004) as amended by MHLW Ordinance No. 128 (2014), Articles 4 to 68 Japan PMD Act (as applicable)
USA	United States	(a) 21 CFR Part 803 (b) 21 CFR Part 806 (c) 21 CFR Part 807 (d) 21 CFR Part 820 (e) 21 CFR Part 821

